Aura Biosciences (AURA) Current Assets (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Current Assets data on file, last reported at $118.5 million in Q1 2026.

• Quarterly Current Assets fell 11.9% year-over-year to $118.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.5 million (down 11.9% YoY) and the FY2025 annual result came in at $149.7 million, down 6.78% from the prior year.
• Current Assets slipped to $118.5 million in Q1 2026, from $149.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $231.8 million in Q4 2023 to a low of $115.9 million in Q3 2022.
• A 5-year average of $165.9 million and a median of $166.2 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets soared 38.88% — and 2025, when it plunged 36.62%.
• Tracing AURA's Current Assets over 5 years: stood at $196.7 million in 2022, then climbed by 17.84% to $231.8 million in 2023, then tumbled by 30.7% to $160.6 million in 2024, then declined by 6.78% to $149.7 million in 2025, then retreated by 20.86% to $118.5 million in 2026.
• The last three Current Assets figures came in at $118.5 million (Q1 2026), $149.7 million (Q4 2025), and $170.1 million (Q3 2025), per Business Quant data.